Aripiprazole Tablets, USP 20 mg Rx Only, packaged as, a) 30-count bottle, NDC 16729-282-10, UPC ...

FDA Recall #D-0369-2023 — Class II — February 7, 2023

Recall #D-0369-2023 Date: February 7, 2023 Classification: Class II Status: Terminated

Product Description

Aripiprazole Tablets, USP 20 mg Rx Only, packaged as, a) 30-count bottle, NDC 16729-282-10, UPC 3 16729 28210 9; b) 100-count bottle, NDC 16729-282-01, UPC 3 16729 28201 7; Manufactured for: Accord Healthcare, Inc., Durham, NC 27703. Manufactured by: Intas Pharmaceuticals Limited, Pharmez, Ahmedabad-382 213. India

Reason for Recall

CGMP Deviations: recalling drug products following an FDA inspection.

Recalling Firm

Accord Healthcare, Inc. — Durham, NC

Classification

Class II — May cause temporary or medically reversible adverse health consequences.

Product Type

Drugs

Product Quantity

170,448 bottles

Distribution

United States including Puerto Rico and Canada

Code Information

Batches: a) P2100787, P2100788, Exp. Date 1/31/2024; P2104736, Exp. Date 6/30/2024; P2105492, Exp. Date 8/31/2024; P2107172, P2107175, Exp. Date 10/31/2024; P2203043, Exp. Date 5/31/2025; b) P2104086 Exp. Date 6/30/2024, P2205370 Exp. 8/31/2025;

Status

Terminated

Voluntary / Mandated

Voluntary: Firm initiated